Intellia Therapeutics, Inc. (NTLA)
Largest Insider Buys in Sector
NTLA Stock Price History Chart
NTLA Stock Performance
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on …
Insider Activity of Intellia Therapeutics, Inc.
Over the last 12 months, insiders at Intellia Therapeutics, Inc. have bought $0 and sold $1.67M worth of Intellia Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Intellia Therapeutics, Inc. have bought $0 and sold $62.96M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 15,000 shares for transaction amount of $235,750 was made by SCHIERMEIER ANDREW (EVP, Dev and Corp Strategy) on 2019‑03‑06.
List of Insider Buy and Sell Transactions, Intellia Therapeutics, Inc.
| 2024-10-02 | Sale | VP, Chief Accounting Officer | 2,012 0.0018% | $19.01 | $38,248 | -5.26% | ||
| 2024-07-01 | Sale | EVP, Chief Technical Officer | 405 0.0004% | $22.93 | $9,287 | 0.00% | ||
| 2024-06-17 | Sale | director | 1,505 0.0016% | $25.00 | $37,625 | -14.74% | ||
| 2024-03-04 | Sale | EVP, General Counsel | 2,297 0.0024% | $32.99 | $75,778 | -28.97% | ||
| 2024-03-04 | Sale | EVP, Chief Technical Officer | 605 0.0006% | $32.99 | $19,959 | -28.97% | ||
| 2024-01-08 | Sale | EVP, Chief Scientific Officer | 2,275 0.0025% | $28.87 | $65,682 | -19.15% | ||
| 2024-01-03 | Sale | President and CEO | 19,223 0.0215% | $29.46 | $566,310 | -17.60% | ||
| 2024-01-03 | Sale | EVP, Chief Medical Officer | 5,843 0.0065% | $29.46 | $172,135 | -17.60% | ||
| 2024-01-03 | Sale | EVP, General Counsel | 3,805 0.0043% | $29.46 | $112,095 | -17.60% | ||
| 2024-01-03 | Sale | EVP, Chief Scientific Officer | 5,532 0.0062% | $29.46 | $162,973 | -17.60% | ||
| 2024-01-03 | Sale | EVP, Chief Technical Officer | 4,608 0.0052% | $29.50 | $135,954 | -17.60% | ||
| 2024-01-03 | Sale | EVP, Chief Financial Officer | 5,365 0.006% | $29.46 | $158,053 | -17.60% | ||
| 2024-01-03 | Sale | EVP, Chief Business Officer | 3,877 0.0043% | $29.46 | $114,216 | -17.60% | ||
| 2023-10-31 | Sale | director | 265 0.0003% | $23.90 | $6,334 | +0.88% | ||
| 2023-07-31 | Sale | director | 265 0.0003% | $42.33 | $11,217 | -34.72% | ||
| 2023-07-06 | Sale | director | 1,867 0.0021% | $39.30 | $73,373 | -27.68% | ||
| 2023-07-03 | Sale | EVP, Chief Technical Officer | 360 0.0004% | $40.51 | $14,584 | -30.45% | ||
| 2023-06-20 | Sale | EVP, Chief Technical Officer | 5,000 0.0059% | $45.00 | $225,000 | -34.07% | ||
| 2023-03-02 | Sale | EVP, General Counsel | 1,088 0.0012% | $43.88 | $47,741 | -18.13% | ||
| 2023-01-05 | Sale | EVP, Chief Scientific Officer | 2,330 0.0026% | $38.48 | $89,659 | -2.68% |
Insider Historical Profitability
| Novartis Institutes for BioMedical Research, Inc. | 10 percent owner | 4129903 4.0549% | $13.87 | 1 | 1 | <0.0001% |
| ORBIMED ADVISORS LLC | director | 2662180 2.6138% | $13.87 | 1 | 0 | <0.0001% |
| GORDON CARL L | director | 2662180 2.6138% | $13.87 | 1 | 0 | <0.0001% |
| BAKER BROS. ADVISORS LP | 976214 0.9585% | $13.87 | 1 | 0 | <0.0001% | |
| Temasek Holdings (Private) Ltd | 10 percent owner | 790527 0.7762% | $13.87 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| ARK Investment Management LLC | $302.32M | 11.39 | 10.99M | -3.71% | -$11.64M | 1.05 | |
| BlackRock | $250.6M | 9.44 | 9.11M | +1.09% | +$2.71M | 0.01 | |
| The Vanguard Group | $250.17M | 9.43 | 9.09M | +8.94% | +$20.53M | 0.01 | |
| State Street | $126.49M | 4.77 | 4.6M | -2.92% | -$3.8M | 0.01 | |
| Deep Track Capital Lp | $115.84M | 4.37 | 4.21M | +87.15% | +$53.94M | 0.53 |